Bacil Pharma proposes R&D arm, but numbers are missing
The nano-cap with zero revenue wants a wholly-owned R&D subsidiary. No investment amount or timeline disclosed, just an intent.
— 6 earlier stories on Bacil Pharma Ltd. →What's new
- Bacil Pharma proposes to incorporate Bacil Research & Development Private Limited as a wholly-owned subsidiary.
- The subsidiary will focus on R&D and allied operations, subject to statutory approvals.
- No financial commitment, investment amount, or revenue projections disclosed.
Why this matters
For a company with zero operating revenue, an R&D subsidiary signals a strategic turn, but the filing is all intent and no detail. Without a disclosed investment or timeline, this remains a placeholder. The market cap of ₹57 cr means even a small cash outlay would matter, yet Bacil hasn't said how much it plans to spend.
What we're watching
- Whether Bacil discloses the investment amount or commits capital to the subsidiary.
- Progress on regulatory approvals from the RoC and other authorities.
- If this is followed by a fundraise, given the company's opaque cash needs.
The full read
Bacil Pharma wants to start an R&D subsidiary. That's the news. But for a company that reported ₹0 crore in sales last quarter and a ₹1 crore net profit that masks operating losses, the filing is an intention, not a plan. Bacil Research & Development Private Limited, a wholly-owned arm, will focus on R&D subject to approvals. What's missing: any investment figure, any timeline, any revenue target. The market cap of ₹57 cr means even a small capital commitment would be material, yet the company has said nothing about how much it will spend. Promoter exits in June 2026, with 5.57% and 2.27% stake sales, add to caution. The idea is interesting. The numbers aren't there yet.
Questions answered
- What is Bacil Pharma's current operational status?
- Bacil Pharma is a nano-cap with no operating revenue. Its latest quarterly sales were ₹0 crore, though it reported a net profit of ₹1 crore in March 2026, likely from non-operating income.
- What does the proposed subsidiary do?
- Bacil Research & Development Private Limited is intended to focus on research and development activities and related allied operations, subject to approval from the Registrar of Companies and other statutory authorities.
- How much will this subsidiary cost?
- The filing did not disclose any investment amount, capital commitment, or revenue projections. It is a preliminary proposal with no financial details.
- Has there been recent insider selling at Bacil?
- Yes. In June 2026, a non-promoter sold a 5.57% stake, and the largest non-promoter investor Nikita Patel cut her holding to 17% in open-market sales.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 18 Jun 2026 · 3:01 PM IST Bacil Pharma proposes R&D arm, but numbers are missing
- today Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 1d ago Bacil Pharma board to mull fundraising options on June 26
- 11d ago Another large Bacil Pharma shareholder sells 5.57% stake
- 13d ago Nikita Patel cuts Bacil Pharma stake to 17% in open-market sale